Biomarkers for Uranium Risk Assessment for the Development of the CURE (Concerted Uranium Research in Europe) Molecular Epidemiological Protocol

Research output: Contribution to journalArticlepeer-review

Standard

Biomarkers for Uranium Risk Assessment for the Development of the CURE (Concerted Uranium Research in Europe) Molecular Epidemiological Protocol. / Guéguen, Yann; Roy, Laurence; Hornhardt, Sabine; Badie, Christophe; Hall, Janet; Baatout, Sarah; Pernot, Eileen; Tomasek, Ladislav; Laurent, Olivier; Ebrahimian, Teni; Ibanez, Chrystelle; Grison, Stephane; Kabacik, Sylwia; Laurier, Dominique; Gomolka, Maria.

In: Radiation Research, Vol. 187, 13.02.2017, p. 107-127.

Research output: Contribution to journalArticlepeer-review

Harvard

Guéguen, Y, Roy, L, Hornhardt, S, Badie, C, Hall, J, Baatout, S, Pernot, E, Tomasek, L, Laurent, O, Ebrahimian, T, Ibanez, C, Grison, S, Kabacik, S, Laurier, D & Gomolka, M 2017, 'Biomarkers for Uranium Risk Assessment for the Development of the CURE (Concerted Uranium Research in Europe) Molecular Epidemiological Protocol', Radiation Research, vol. 187, pp. 107-127. https://doi.org/10.1667/RR14505.1

APA

Guéguen, Y., Roy, L., Hornhardt, S., Badie, C., Hall, J., Baatout, S., Pernot, E., Tomasek, L., Laurent, O., Ebrahimian, T., Ibanez, C., Grison, S., Kabacik, S., Laurier, D., & Gomolka, M. (2017). Biomarkers for Uranium Risk Assessment for the Development of the CURE (Concerted Uranium Research in Europe) Molecular Epidemiological Protocol. Radiation Research, 187, 107-127. https://doi.org/10.1667/RR14505.1

Author

Guéguen, Yann ; Roy, Laurence ; Hornhardt, Sabine ; Badie, Christophe ; Hall, Janet ; Baatout, Sarah ; Pernot, Eileen ; Tomasek, Ladislav ; Laurent, Olivier ; Ebrahimian, Teni ; Ibanez, Chrystelle ; Grison, Stephane ; Kabacik, Sylwia ; Laurier, Dominique ; Gomolka, Maria. / Biomarkers for Uranium Risk Assessment for the Development of the CURE (Concerted Uranium Research in Europe) Molecular Epidemiological Protocol. In: Radiation Research. 2017 ; Vol. 187. pp. 107-127.

Bibtex - Download

@article{ac387b64b1be43a5848f72897dce9fd2,
title = "Biomarkers for Uranium Risk Assessment for the Development of the CURE (Concerted Uranium Research in Europe) Molecular Epidemiological Protocol",
abstract = "Despite substantial experimental and epidemiological research, there is limited knowledge of the uranium-induce health effects after chronic low-dose exposures in humans. Biological markers can objectively characterize pathological processes or environmental responses to uranium and confounding agents. The integration of such biological markers into a molecular epidemiological study would be a useful approach to improve and refine estimations of uranium-induced health risks. To initiate such a study, Concerted Uranium Research in Europe (CURE) was established, and involves biologists, epidemiologists and dosimetrists. The aims of the biological work package of CURE were: 1. To identify biomarkers and biological specimens elevant to uranium exposure; 2. To define standard operating procedures (SOPs); and 3. To set up a common protocol (logistic, questionnaire, ethical aspects) to perform a large-scale molecular epidemiologic study in uranium-exposed cohorts. An intensive literature review was performed and led to the identification of biomarkers related to: 1. retention organs (lungs, kidneys and bone); 2. other systems/organs with suspected effects (cardiovascular system, central nervous system and lympho-hematopoietic system); 3. target molecules (DNA damage, genomic instability); and 4. high-throughput methods for the identification of new biomarkers. To obtain high-quality biological materials, SOPs were established for the sampling and storage of different biospecimens. A questionnaire was developed to assess potential confounding factors. The proposed strategy can be adapted to other internal exposures and should improve the characterization of the biological and health effects that are relevant for risk assessment.",
keywords = "biomarker, radiobiology",
author = "Yann Gu{\'e}guen and Laurence Roy and Sabine Hornhardt and Christophe Badie and Janet Hall and Sarah Baatout and Eileen Pernot and Ladislav Tomasek and Olivier Laurent and Teni Ebrahimian and Chrystelle Ibanez and Stephane Grison and Sylwia Kabacik and Dominique Laurier and Maria Gomolka",
note = "Score=10",
year = "2017",
month = feb,
day = "13",
doi = "10.1667/RR14505.1",
language = "English",
volume = "187",
pages = "107--127",
journal = "Radiation Research",
issn = "0033-7587",
publisher = "RADRES - Radiation Research Society",

}

RIS - Download

TY - JOUR

T1 - Biomarkers for Uranium Risk Assessment for the Development of the CURE (Concerted Uranium Research in Europe) Molecular Epidemiological Protocol

AU - Guéguen, Yann

AU - Roy, Laurence

AU - Hornhardt, Sabine

AU - Badie, Christophe

AU - Hall, Janet

AU - Baatout, Sarah

AU - Pernot, Eileen

AU - Tomasek, Ladislav

AU - Laurent, Olivier

AU - Ebrahimian, Teni

AU - Ibanez, Chrystelle

AU - Grison, Stephane

AU - Kabacik, Sylwia

AU - Laurier, Dominique

AU - Gomolka, Maria

N1 - Score=10

PY - 2017/2/13

Y1 - 2017/2/13

N2 - Despite substantial experimental and epidemiological research, there is limited knowledge of the uranium-induce health effects after chronic low-dose exposures in humans. Biological markers can objectively characterize pathological processes or environmental responses to uranium and confounding agents. The integration of such biological markers into a molecular epidemiological study would be a useful approach to improve and refine estimations of uranium-induced health risks. To initiate such a study, Concerted Uranium Research in Europe (CURE) was established, and involves biologists, epidemiologists and dosimetrists. The aims of the biological work package of CURE were: 1. To identify biomarkers and biological specimens elevant to uranium exposure; 2. To define standard operating procedures (SOPs); and 3. To set up a common protocol (logistic, questionnaire, ethical aspects) to perform a large-scale molecular epidemiologic study in uranium-exposed cohorts. An intensive literature review was performed and led to the identification of biomarkers related to: 1. retention organs (lungs, kidneys and bone); 2. other systems/organs with suspected effects (cardiovascular system, central nervous system and lympho-hematopoietic system); 3. target molecules (DNA damage, genomic instability); and 4. high-throughput methods for the identification of new biomarkers. To obtain high-quality biological materials, SOPs were established for the sampling and storage of different biospecimens. A questionnaire was developed to assess potential confounding factors. The proposed strategy can be adapted to other internal exposures and should improve the characterization of the biological and health effects that are relevant for risk assessment.

AB - Despite substantial experimental and epidemiological research, there is limited knowledge of the uranium-induce health effects after chronic low-dose exposures in humans. Biological markers can objectively characterize pathological processes or environmental responses to uranium and confounding agents. The integration of such biological markers into a molecular epidemiological study would be a useful approach to improve and refine estimations of uranium-induced health risks. To initiate such a study, Concerted Uranium Research in Europe (CURE) was established, and involves biologists, epidemiologists and dosimetrists. The aims of the biological work package of CURE were: 1. To identify biomarkers and biological specimens elevant to uranium exposure; 2. To define standard operating procedures (SOPs); and 3. To set up a common protocol (logistic, questionnaire, ethical aspects) to perform a large-scale molecular epidemiologic study in uranium-exposed cohorts. An intensive literature review was performed and led to the identification of biomarkers related to: 1. retention organs (lungs, kidneys and bone); 2. other systems/organs with suspected effects (cardiovascular system, central nervous system and lympho-hematopoietic system); 3. target molecules (DNA damage, genomic instability); and 4. high-throughput methods for the identification of new biomarkers. To obtain high-quality biological materials, SOPs were established for the sampling and storage of different biospecimens. A questionnaire was developed to assess potential confounding factors. The proposed strategy can be adapted to other internal exposures and should improve the characterization of the biological and health effects that are relevant for risk assessment.

KW - biomarker

KW - radiobiology

UR - http://ecm.sckcen.be/OTCS/llisapi.dll?func=ll&objId=22495553&objaction=overview&tab=1

U2 - 10.1667/RR14505.1

DO - 10.1667/RR14505.1

M3 - Article

VL - 187

SP - 107

EP - 127

JO - Radiation Research

JF - Radiation Research

SN - 0033-7587

ER -

ID: 2122742